POPLAR: 3-year survival and duration of response data

In the 3-year-survival analysis of the phase II study POPLAR atezolizumab demonstrated superior 2-year and 3-year overall survival (OS) benefit compared with docetaxel in patients with advanced NSCLC. This benefit was observed across histology and PD-L1 expression subgroups (including TC0 and IC0). Atezolizumab was well tolerated, and responses were highly durable. These results are consistent with long-term OS results from the phase III study OAK.

Results

The 2-year and 3-year survival with atezolizumab (1200 mg) vs docetaxel (75 mg/m²) IV y3w were 32.2% vs 16.6% and 18.7% vs 10.0%, respectively. The long-term OS benefit of atezolizumab vs docetaxel was observed across histology and PD-L1 expression subgroups. While the TC3 or IC3 subgroup derived the greatest OS benefit, the TC0 and IC0 subgroup also had improved long-term OS with atezolizumab vs docetaxel. The ITT ORR was 15 % in both atezolizumab and docetaxel arms, but the median duration of response was 3 times longer with atezolizumab (22.3 months [95 % CI: 11.6, 31.1] vs 7.2 months [95 % CI: 5.8, 12.2] with docetaxel). Seven of the 11 docetaxel-arm 3-year survivors received subsequent non-protocol therapy with anti–PD-L1/PD-1 agents. Atezolizumab had a favourable safety profile compared with docetaxel that was consistent with previous reports.